Sinotherapeutics Past Earnings Performance
Past criteria checks 3/6
Sinotherapeutics has been growing earnings at an average annual rate of 1.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 12.6% per year. Sinotherapeutics's return on equity is 8.9%, and it has net margins of 24.4%.
Key information
1.9%
Earnings growth rate
-1.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 12.6% |
| Return on equity | 8.9% |
| Net Margin | 24.4% |
| Next Earnings Update | 06 Dec 2024 |
Revenue & Expenses Breakdown
How Sinotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 449 | 110 | 52 | 87 |
| 30 Jun 24 | 407 | 92 | 49 | 80 |
| 31 Mar 24 | 369 | 76 | 48 | 79 |
| 31 Dec 23 | 300 | 61 | 45 | 74 |
| 30 Sep 23 | 274 | 70 | 44 | 68 |
| 30 Jun 23 | 230 | 76 | 41 | 68 |
| 31 Mar 23 | 227 | 80 | 42 | 68 |
| 31 Dec 22 | 248 | 93 | 46 | 76 |
| 30 Sep 22 | 271 | 141 | 43 | 82 |
| 30 Jun 22 | 287 | 138 | 43 | 86 |
| 31 Mar 22 | 301 | 137 | 43 | 96 |
| 31 Dec 21 | 315 | 135 | 46 | 104 |
| 31 Dec 20 | 319 | 123 | 57 | 76 |
| 31 Dec 19 | 139 | 5 | 54 | 51 |
| 31 Dec 18 | 61 | -37 | 33 | 50 |
Quality Earnings: 688247 has a high level of non-cash earnings.
Growing Profit Margin: 688247's current net profit margins (24.4%) are lower than last year (25.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688247 has become profitable over the past 5 years, growing earnings by 1.9% per year.
Accelerating Growth: 688247's earnings growth over the past year (56.7%) exceeds its 5-year average (1.9% per year).
Earnings vs Industry: 688247 earnings growth over the past year (56.7%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 688247's Return on Equity (8.9%) is considered low.